Susanne Lingelbach-Eder
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals.
A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals.
Journal: Nature communications
Published: April 14, 2026
Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial.
Journal: Nature medicine
Published: July 07, 2025
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil.
Journal: The Lancet. Infectious diseases
Published: June 02, 2025
Intestinal inflammation induced by heat-labile toxin-producing enterotoxigenic E: Coli infection and impact on immune responses in an experimental human challenge model.
Journal: PLoS neglected tropical diseases
Published: April 17, 2025
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Journal: The Lancet. Infectious diseases
Published: April 01, 2025
Immunogenicity and safety of different immunisation schedules of the VLA15 Lyme borreliosis vaccine candidate in adults, adolescents, and children: a randomised, observer-blind, placebo-controlled, phase 2 trial.
Journal: The Lancet. Infectious diseases
Published: October 21, 2024
Pooled safety evaluation for a new single-shot live-attenuated chikungunya vaccine†.
Journal: Journal of travel medicine
Published: July 31, 2024
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents.
Journal: The Lancet. Infectious diseases
Published: May 16, 2024
Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine.
Journal: Journal of travel medicine
Published: May 01, 2024
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial.
Journal: The Lancet. Infectious diseases
Published: April 09, 2024
Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study.
Journal: The Lancet. Infectious diseases
Published: March 19, 2024
Last Updated: 09/26/2026